Moderna(MRNA.O)：H5禽流感疫苗第一/二期临床试验显示初步积极结果，将探索H5项目后期开发和制造的替代方案，美国卫生与公众服务部将终止公司用于疫情前流感疫苗后期开发的资助。

Core Viewpoint - Moderna's H5 avian influenza vaccine has shown preliminary positive results in Phase I/II clinical trials, prompting the company to explore alternative options for late-stage development and manufacturing of the H5 project [1] Group 1: Clinical Trial Results - The initial results from the Phase I/II clinical trials for the H5 avian influenza vaccine are encouraging, indicating potential for further development [1] Group 2: Funding and Development - The U.S. Department of Health and Human Services will terminate funding for Moderna's late-stage development of the pre-pandemic flu vaccine [1]